Portal de Periódicos da CAPES

MSC Based Therapies—New Perspectives for the Injured Lung

2020; Multidisciplinary Digital Publishing Institute; Volume: 9; Issue: 3 Linguagem: Inglês

10.3390/jcm9030682

2077-0383

Judith Behnke, Sarah Kremer, Tayyab Shahzad, Cho‐Ming Chao, Eva Böttcher‐Friebertshäuser, Rory E. Morty, Savério Bellusci, Harald Ehrhardt,

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Chronic lung diseases pose a tremendous global burden. At least one in four people suffer from severe pulmonary sequelae over the course of a lifetime. Despite substantial improvements in therapeutic interventions, persistent alleviation of clinical symptoms cannot be offered to most patients affected to date. Despite broad discrepancies in origins and pathomechanisms, the important disease entities all have in common the pulmonary inflammatory response which is central to lung injury and structural abnormalities. Mesenchymal stem cells (MSC) attract particular attention due to their broadly acting anti-inflammatory and regenerative properties. Plenty of preclinical studies provided congruent and convincing evidence that MSC have the therapeutic potential to alleviate lung injuries across ages. These include the disease entities bronchopulmonary dysplasia, asthma and the different forms of acute lung injury and chronic pulmonary diseases in adulthood. While clinical trials are so far restricted to pioneering trials on safety and feasibility, preclinical results point out possibilities to boost the therapeutic efficacy of MSC application and to take advantage of the MSC secretome. The presented review summarizes the most recent advances and highlights joint mechanisms of MSC action across disease entities which provide the basis to timely tackle this global disease burden.